Drug pricing policies are reshaping the life sciences landscape in many ways. From the United States’ Most-Favored-Nation (MFN) policy to evolving international frameworks, these decisions are influencing everything from commercialization strategies to investment valuations.

In this exclusive RBCx client webinar, industry experts David Dean, VP of Business Development at Eupraxia Pharmaceuticals Inc., Sarah Lawrie, Principal at Rosenblatt Life Science, Anne Woods, Managing Director, Life Sciences at RBCx and Abood Mohamed, VP, Life Sciences explore the global drug pricing models that matter most to your organization. You’ll gain practical insights into navigating pricing complexities, understanding regional policy impacts, and positioning your go-to-market approach for success in an evolving regulatory environment.

Whether you’re developing breakthrough therapies or guiding strategic investment decisions, this conversation offers the perspectives you need to move forward with confidence.

RBCx offers support to startups in all stages of growth, backing some of Canada’s most daring tech companies and idea generators. We turn our experience, networks, and capital into your competitive advantage to help you scale and make a meaningful impact on the world. Speak with an RBCx Advisor to learn more about how we can help your business grow.

This article is intended as general information only and is not to be relied upon as constituting legal, financial or other professional advice. The reader is solely liable for any use of the information contained in this document and Royal Bank of Canada (“RBC”) nor any of its affiliates nor any of their respective directors, officers, employees or agents shall be held responsible for any direct or indirect damages arising from the use of this document by the reader. A professional advisor should be consulted regarding your specific situation. Information presented is believed to be factual and up-to-date but we do not guarantee its accuracy and it should not be regarded as a complete analysis of the subjects discussed. All expressions of opinion reflect the judgment of the authors as of the date of publication and are subject to change. No endorsement of any third parties or their advice, opinions, information, products or services is expressly given or implied by Royal Bank of Canada or any of its affiliates.